Topics:

Lung Cancer

Older Early-Stage NSCLC Patients Benefit From Adjuvant Chemotherapy

Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection. Image © pruit phatsrivong / Shutterstock.com.

Lung Cancer

In this video from the 2015 ONS meeting, Dr. Sipples talks about effective management of side effects for patients taking afatinib, an oral, targeted agent for lung cancer.

Patients with lung cancer are increasingly receiving targeted therapies that induce complete disease remissions, but they can also develop resistance to these drugs. New efforts are now underway to discover and develop new options for patients experiencing drug resistance.

Inhibition of PD-1 with pembrolizumab was well tolerated and showed promising survival results in a large phase I trial of patients with advanced non–small-cell lung cancer (NSCLC).

Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.

Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection.

Though surgery is the standard treatment for early-stage non-small-cell lung cancer, a new study suggests that stereotactic body radiotherapy offers lower immediate mortality and toxicity.

In this interview we discuss the recent CMS decision to cover low-dose CT screening for lung cancer in patients who fit specific criteria.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.